Ginkgo Bioworks DNA
$7.46 −$0.74 (-9.02%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.55 +1.21%
Open$7.93
Prev close$8.20
Day range$7.38 – $8.29
Volume2.51M
Market cap$483.59M
P/E (TTM)–
Dividend yield–
DNA Stock News
Headlines matching Ginkgo Bioworks or the DNA ticker, most recent first.
- BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $5
- Kala Bio and Virotek Sign Letter of Intent With U.S. DNA Testing Platform to Resell Virotek's Suite of Genetic Testing Products
- TD Cowen Downgrades Ginkgo Bioworks(DNA.US) to Hold Rating, Cuts Target Price to $9 Negative
- William Blair Initiates Ginkgo Bioworks(DNA.US) With Sell Rating
- Press Release: DNA X, Inc. Reports Second Quarter 2026 Financial Results
- William Blair Maintains Ginkgo Bioworks(DNA.US) With Sell Rating
- Ginkgo Bioworks (DNA.US) will release its earnings report after market close on August 5.
- TD Cowen Maintains Ginkgo Bioworks(DNA.US) With Buy Rating, Maintains Target Price $12
- DNA X | 8-K: DNA X, Inc. Reports First Quarter 2026 Financial Results
- Analysts Conflicted on These Healthcare Names: Ginkgo Bioworks Holdings (DNA), Xencor (XNCR) and Alto Neuroscience, Inc. (ANRO)
- BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Cuts Target Price to $5 Negative
- Sonim Technologies | 3: Initial statement of beneficial ownership of securities-10% Owner DNA Holdings Venture Inc.
- Health Weekly Report | Domestic lung cancer detection products approved; regulations established for cancer vaccine development; breakthrough in DNA immunotherapy. Positive
- Google DeepMind releases AlphaGenome 2: capable of interpreting DNA at the cellular level, with variant identification performance nearly doubled.
- Trade.xyz announces the listing of synthetic DNA company TWST.
No comments yet — be the first to weigh in on DNA.
Sign in to join the discussion.